iOmx Therapeutics AG, a clinical stage biopharmaceutical company, has appointed Nils Peter Debus as chief business officer effective 5 September. Dr Debus will help to drive iOmx’s new stage of growth to leverage its iOTarg platform to address novel immune checkpoints on myeloid cells and advance its first checkpoint inhibitor into the clinic. He brings 27 years life science experience and was previously CBO at OSE Immunotherapeutics. Dr Debus also held senior business development positions at Boehringer Ingelheim and Merz Pharmaceuticals. He holds a PhD in embryonic stem cell research from Humboldt University, Berlin, Germany, and received training in corporate finance from Duke University, US.
Copyright 2023 Evernow Publishing Ltd